Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 13/20 | 0.43 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.42 |
| ▸ | GSK3B | P49841 | 4/20 | 0.39 |
| ▸ | WNT1 | P04628 | 2/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.39 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.38 |
| ▸ | CDK4 | P11802 | 1/20 | 0.38 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.38 |
| ▸ | CCND1 | P24385 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | CDK9 | P50750 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15050990 | 0.88 | ABL1 (0.42) | ABL1PIK3C3GSK3BWNT1DYRK1A | |
| SCHEMBL15050804 | 0.83 | ABL1 (0.43) | ABL1PIK3C3GSK3BWNT1DYRK1A | |
| SCHEMBL15050952 | 0.81 | PIK3C3 (0.42) | ABL1PIK3C3CCNT1CDK4CCND1 | |
| SCHEMBL15051751 | 0.71 | ABL1 (0.42) | ABL1PIK3C3 | |
| SCHEMBL627636 | 0.66 | ABL1 (0.47) | ABL1 | |
| SCHEMBL15051050 | 0.65 | ABL1 (0.43) | ABL1PIK3C3 | |
| SCHEMBL9109468 | 0.62 | NPC1 (0.39) | ABL1PIK3C3 | |
| SCHEMBL15050809 | 0.62 | PIK3C3 (0.52) | PIK3C3 | |
| SCHEMBL15051493 | 0.61 | ABL1 (0.47) | ABL1 | |
| SCHEMBL624567 | 0.61 | NPC1 (0.54) | ABL1GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2793879-A1 | HETEROARYLS AND USES THEREOF | Millennium Pharmaceuticals, Inc. (US) | 2014-10-29 | — | — | EP | disclosed |
| WO-2013096637-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | WO | disclosed |
| WO-2013096637-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | WO | disclosed |
| US-20130165483-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130165483-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165483-A1 | HETEROARYLS AND USES THEREOF | PIK3R5, PIK3R4, PIK3C2B | ABL1 711/4885PIK3C3 143/4885GSK3B 547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.